Luminopia, Inc., a digital health company pioneering a new class of treatments for neuro-visual disorders, today announced that the U.S. Food & Drug Administration (FDA) cleared its amblyopia ...

Luminopia One can now be prescribed to improve visual acuity in children aged 4-7 with amblyopia associated with mild strabismus – or crossed eyes – and/or a condition called anisometropia ...

Amblyopia was associated with anisometropia in 18 (5.5 (1.4) years), strabismus in 16 (4.2 (0.98) years), and mixed in 31 (5.2 (1.5) years) of the study participants. Mean (SD) corrected visual acuity ...